
|Videos|July 12, 2016
Dr. George D. Demetri on the Impact of Sarcoma Subtyping on Other Cancers
Author(s)George D. Demetri, MD
Advertisement
George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, explains how sarcoma treatment has influenced the treatment of other cancers.
Sarcoma continues to pave the way for what is happening in other cancers, says Demetri. The disease is broken down into over 500 different subtypes, each with their own treatment specifications. This method is now being applied in lung, breast, and colorectal cancers, says Demetri.
Some cancers have also been decommissioned, and are not longer consider carcinomas at all.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5




































